Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Lantern Pharma ( (LTRN) ).
Lantern Pharma Inc.’s Board of Directors has approved an amendment to the employment agreement for Kishor G. Bhatia, the Chief Scientific Officer. The amendment extends the agreement’s term to January 15, 2026, adjusts his working hours to 24 per week, and sets his annual base salary at $189,600, effective from the first pay period in January 2025.
More about Lantern Pharma
YTD Price Performance: 18.79%
Average Trading Volume: 64,534
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $42.28M
Learn more about LTRN stock on TipRanks’ Stock Analysis page.